Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quanterix CorpQTRX · Entity 6649 | Director | July 08, 2026 | July 09, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Director | May 04, 2026 | May 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quanterix Corp
Report date July 08, 2026 · Filed July 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,041 |
Reported balance
After 2026-07-08 transaction · row 1
1 source rowRow 1 · 2026-07-08 · Exercise / conversion · Acquired 8,073 · Balance 15,041 F1: Restricted stock units convert into common stock on a one-for-one basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 16,391 |
Reported balance
After 2026-07-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-08 · Exercise / conversion · Disposed 8,073 · Balance 16,391 F2: On July 8, 2025, the reporting person was granted 24,464 restricted stock units, vesting 33%, 33%, and 34% on the first, second, and third anniversaries of the grant date, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units convert into common stock on a one-for-one basis.
F2: On July 8, 2025, the reporting person was granted 24,464 restricted stock units, vesting 33%, 33%, and 34% on the first, second, and third anniversaries of the grant date, respectively.
WEST PHARMACEUTICAL SERVICES INC
Report date May 04, 2026 · Filed May 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,434.587 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 791 · Balance 20,434.587 F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akoya Biosciences, Inc.
Report date July 08, 2025 · Filed July 11, 2025
Section 16 reporting ended · disclosed 2025-07-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 1
1 source rowRow 1 · 2025-07-08 · Other · Disposed 20,000 · Balance 0 F1: Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix. F2: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.10 · Expires 2031-09-16 | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-07-08 · Other · Disposed 38,993 · Balance 0 F3: Disposition of options pursuant to Merger Agreement. F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.24 · Expires 2032-06-01 | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-07-08 · Other · Disposed 30,549 · Balance 0 F3: Disposition of options pursuant to Merger Agreement. F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.70 · Expires 2033-06-01 | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-07-08 · Other · Disposed 56,322 · Balance 0 F3: Disposition of options pursuant to Merger Agreement. F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2034-06-04 | Direct | 0 |
Reported balance
After 2025-07-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-07-08 · Other · Disposed 50,000 · Balance 0 F3: Disposition of options pursuant to Merger Agreement. F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.
F2: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement.
F3: Disposition of options pursuant to Merger Agreement.
F4: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration.
SEQUENOM INC
Report date September 07, 2016 · Filed September 07, 2016
Section 16 reporting ended · disclosed 2016-09-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 1
1 source rowRow 1 · 2016-09-07 · Other · Disposed 79,579 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2026-06-14 | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-07 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 9, 2026 21:19 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionRestricted Stock Unit · Derivative | 8,073 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001168581-26-000002 · primarydocument.xml · derivative · entry 2 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,391 Underlying: Common Stock · 8,073 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On July 8, 2025, the reporting person was granted 24,464 restricted stock units, vesting 33%, 33%, and 34% on the first, second, and third anniversaries of the grant date, respectively. F2 · derivative.expiration_date: On July 8, 2025, the reporting person was granted 24,464 restricted stock units, vesting 33%, 33%, and 34% on the first, second, and third anniversaries of the grant date, respectively. Read SEC document |
| July 08, 2026 Filed Jul 9, 2026 21:19 UTC | Quanterix Corp QTRX · Entity 6649 | Exercise / conversionCommon Stock | 8,073 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001168581-26-000002 · primarydocument.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 04, 2026 Filed May 6, 2026 21:32 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 791 | $0.00 | $0.00 |
DisclosureSEC source: 0000105770-26-000063 · form4.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,434.587 F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:46 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 1,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001168581-26-000001 · primarydocument.xml · nonDerivative · entry 2 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,804 F3 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the fourth quarter of 2025. F2 · balance_after: Includes 47,836 restricted stock units. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:46 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 23,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001168581-26-000001 · primarydocument.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,860 F1 · shares: Represents restricted stock units that vest as to 100% of the shares on January 2, 2027 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 47,836 restricted stock units. Read SEC document |
| October 01, 2025 Filed Oct 4, 2025 00:54 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,084 | $5.54 | $11,545.36 |
DisclosureSEC source: 0001168581-25-000003 · primarydocument.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,488 F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the third quarter of 2025. F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on October 1, 2025. F3 · balance_after: Includes 24,464 restricted stock units. Read SEC document |
| July 08, 2025 Filed Jul 11, 2025 00:39 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (right to buy) · Derivative | 50,758 | $0.00 Strike: $6.54 | $0.00 |
DisclosureSEC source: 0001562180-25-005380 · primarydocument.xml · derivative · entry 3 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,758 Underlying: Common Stock · 50,578 shares Expires 2035-07-08 F4 · derivative.exercise_date: The option vests as to one-third of the shares on July 8, 2026, and the remaining two-thirds of the shares vest monthly thereafter over two years in 24 successive equal installments. Read SEC document |
| July 08, 2025 Filed Jul 11, 2025 00:39 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 24,464 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-005380 · primarydocument.xml · nonDerivative · entry 2 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,404 F2 · shares: Represents shares of stock issuable on vesting of restricted stock units. The restricted stock units vest as to one-third of the shares on each of July 8, 2026, July 8, 2027 and July 8, 2028. F3 · balance_after: Includes 24,464 restricted stock units. Read SEC document |
| July 08, 2025 Filed Jul 11, 2025 00:39 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 2,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-005380 · primarydocument.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,940 F1 · price: Received in exchange for 20,000 shares of Akoya Biosciences, Inc. ("Akoya") common stock in connection with the acquisition of Akoya by Quanterix on July 8, 2025. Dr. Lai-Goldman received: (a) 0.1470 of a share of Quanterix common stock and (b) $0.37 in cash, for each share of Akoya common stock. The closing price of the Quanterix common stock on July 8, 2025 was $6.54 per share. The closing price of the Akoya common stock on July 7, 2025 was $1.29 per share. Read SEC document |
| July 08, 2025 Filed Jul 11, 2025 00:37 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | OtherStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001062993-25-012722 · form4.xml · derivative · entry 5 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2034-06-04 F3 · kind: Disposition of options pursuant to Merger Agreement. F4 · shares: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. Read SEC document |
| July 08, 2025 Filed Jul 11, 2025 00:37 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | OtherStock Option (right to buy) · Derivative | 56,322 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001062993-25-012722 · form4.xml · derivative · entry 4 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,322 shares Expires 2033-06-01 F3 · kind: Disposition of options pursuant to Merger Agreement. F4 · shares: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. Read SEC document |
| July 08, 2025 Filed Jul 11, 2025 00:37 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | OtherStock Option (right to buy) · Derivative | 30,549 | $0.00 Strike: $11.24 | $0.00 |
DisclosureSEC source: 0001062993-25-012722 · form4.xml · derivative · entry 3 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,549 shares Expires 2032-06-01 F3 · kind: Disposition of options pursuant to Merger Agreement. F4 · shares: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. Read SEC document |
| July 08, 2025 Filed Jul 11, 2025 00:37 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | OtherStock Option (Right to Buy) · Derivative | 38,993 | $0.00 Strike: $18.10 | $0.00 |
DisclosureSEC source: 0001062993-25-012722 · form4.xml · derivative · entry 2 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 38,993 shares Expires 2031-09-16 F3 · kind: Disposition of options pursuant to Merger Agreement. F4 · shares: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration was automatically terminated and cancelled for no consideration. Read SEC document |
| July 08, 2025 Filed Jul 11, 2025 00:37 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | OtherCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-25-012722 · form4.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix. F2 · price: In connection with the terms of the Merger Agreement, each share of common stock of Issuer outstanding on the Closing Date was converted into the right to receive (a) 0.1461 of a share of common stock of Quanterix (the "Per Share Stock Consideration") and (b) $0.38 in cash, without interest (the "Per Share Cash Consideration" and together with the Per Share Stock Consideration, the "Per Share Merger Consideration"). Each of the Per Share Stock Consideration and the Per Share Cash Consideration may be adjusted pursuant to the terms of the Merger Agreement. Read SEC document |
| May 06, 2025 Filed May 8, 2025 20:42 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-013709 · form4.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,423.93 F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| June 04, 2024 Filed Jun 5, 2024 21:54 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $2.01 | $0.00 |
DisclosureSEC source: 0001104659-24-068746 · tm2416554-2_4seq1.xml · derivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 4, 2025, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant. Read SEC document |
| April 23, 2024 Filed Apr 25, 2024 20:49 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 564 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-013406 · form4.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,352.93 F1 · shares: These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| June 12, 2023 Filed Jun 12, 2023 22:18 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | PurchaseCommon Stock | 20,000 | $5.00 | $100,000.00 |
DisclosureSEC source: 0001104659-23-070484 · tm2318472-5_4seq1.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 21:43 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | GrantStock Option (Right to Buy) · Derivative | 56,322 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001104659-23-068163 · tm2317841-3_4seq1.xml · derivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,322 Underlying: Common Stock · 56,322 shares Expires 2033-06-01 F1 · derivative.exercise_date: Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2024, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant. Read SEC document |
| April 25, 2023 Filed Apr 27, 2023 21:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 616 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-23-003696 · primarydocument.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,788.93 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of the grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:06 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | GrantStock Option (Right to Buy · Derivative | 30,549 | $0.00 Strike: $11.24 | $0.00 |
DisclosureSEC source: 0001104659-22-068077 · tm2217652-5_4seq1.xml · derivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,549 Underlying: Common Stock · 30,549 shares Expires 2032-06-01 F1 · derivative.exercise_date: Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2023, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant. Read SEC document |
| May 24, 2022 Filed May 26, 2022 19:49 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 632 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-22-004429 · primarydocument.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,172.93 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| September 16, 2021 Filed Sep 21, 2021 00:51 UTC | Akoya Biosciences, Inc. AKYA · Entity 77553 | GrantStock Option (Right to Buy · Derivative | 38,993 | $0.00 Strike: $18.10 | $0.00 |
DisclosureSEC source: 0001104659-21-117549 · tm2128081-2_4seq1.xml · derivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,993 Underlying: Common Stock · 38,993 shares Expires 2031-09-16 F1 · derivative.exercise_date: Subject to the reporting person's continuous service through the vesting date, the options shall vest in three (3) equal installments beginning on September 16, 2022 and annually thereafter until fully vested. Read SEC document |
| May 04, 2021 Filed May 6, 2021 23:28 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 577 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-21-003309 · primarydocument.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,540.93 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| May 05, 2020 Filed May 7, 2020 22:06 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-20-003466 · primarydocument.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,927.5992 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| May 07, 2019 Filed May 9, 2019 19:11 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,565 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-19-002730 · primarydocument.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,943.0115 F1 · price: These shares of restricted stock units will vest in full on the first anniversary of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| May 01, 2018 Filed May 3, 2018 21:45 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-002196 · primarydocument.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,378.0115 F1 · price: These shares of restricted stock units will vest in full on the first anniversay of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. F1 · balance_after: These shares of restricted stock units will vest in full on the first anniversay of the date of grant and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| December 29, 2017 Filed Aug 1, 2018 20:35 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 103.2362 | $99.16 | $10,236.90 |
DisclosureSEC source: 0001562180-18-003449 · primarydocument.xml · derivative · entry 2 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,832.0826 Underlying: Common Stock · 103.2362 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. Read SEC document |
| September 29, 2017 Filed Oct 3, 2017 19:53 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 103.8098 | $96.33 | $10,000.00 |
DisclosureSEC source: 0001562180-17-003161 · primarydocument.xml · derivative · entry 2 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,728.8464 Underlying: Common Stock · 103.8098 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 16:39 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 105.9434 | $94.39 | $10,000.00 |
DisclosureSEC source: 0001562180-17-002374 · primarydocument.xml · derivative · entry 2 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,622.6151 Underlying: Common Stock · 105.9434 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| May 02, 2017 Filed May 3, 2017 18:56 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-001689 · primarydocument.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,528.9468 F1 · price: These shares of restricted stock units will vest in full after 12 months and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 19:16 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 122.414 | $81.69 | $10,000.00 |
DisclosureSEC source: 0001562180-17-001423 · primarydocument.xml · derivative · entry 2 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,514.5777 Underlying: Common Stock · 122.414 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| December 30, 2016 Filed Jan 4, 2017 19:56 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 117.3709 | $85.20 | $10,000.00 |
DisclosureSEC source: 0001562180-17-000145 · primarydocument.xml · derivative · entry 2 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,390.028 Underlying: Common Stock · 117.3709 shares Expires not disclosed F2 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 19:07 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantPhantom Stock Unit · Derivative | 134.9164 | $74.12 | $10,000.00 |
DisclosureSEC source: 0001225208-16-039974 · doc4.xml · derivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,268.7644 Underlying: Common Stock · 134.9164 shares Expires not disclosed F1 · derivative.exercise_price: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.exercise_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F1 · derivative.expiration_date: Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:34 UTC | SEQUENOM INC SQNM · Entity 182543 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $1.11 | Not disclosed |
DisclosureSEC source: 0001209191-16-140402 · doc4.xml · derivative · entry 2 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-06-14 F2 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F2 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:34 UTC | SEQUENOM INC SQNM · Entity 182543 | OtherCommon Stock | 79,579 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-140402 · doc4.xml · nonDerivative · entry 1 LAI GOLDMAN MYLA · CIK 0001168581 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.